Perspective Therapeutics Statistics Share Statistics Perspective Therapeutics has 74.23M
shares outstanding. The number of shares has increased by 10.09%
in one year.
Shares Outstanding 74.23M Shares Change (YoY) 10.09% Shares Change (QoQ) 0.24% Owned by Institutions (%) n/a Shares Floating 57.59M Failed to Deliver (FTD) Shares 2,598 FTD / Avg. Volume 0.22%
Short Selling Information The latest short interest is 6.35M, so 8.55% of the outstanding
shares have been sold short.
Short Interest 6.35M Short % of Shares Out 8.55% Short % of Float 12.11% Short Ratio (days to cover) 5.38
Valuation Ratios The PE ratio is -2.59 and the forward
PE ratio is -2.85.
Perspective Therapeutics's PEG ratio is
-0.06.
PE Ratio -2.59 Forward PE -2.85 PS Ratio 0 Forward PS 267.1 PB Ratio 0.71 P/FCF Ratio -2.83 PEG Ratio -0.06
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Perspective Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 12.68,
with a Debt / Equity ratio of 0.01.
Current Ratio 12.68 Quick Ratio 12.68 Debt / Equity 0.01 Debt / EBITDA 0.23 Debt / FCF -0.03 Interest Coverage -217.9
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-574.49K Employee Count 138 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax -2.1M Effective Tax Rate 2.58%
Stock Price Statistics The stock price has increased by -69.23% in the
last 52 weeks. The beta is 1.18, so Perspective Therapeutics's
price volatility has been higher than the market average.
Beta 1.18 52-Week Price Change -69.23% 50-Day Moving Average 3.65 200-Day Moving Average 3.98 Relative Strength Index (RSI) 45.53 Average Volume (20 Days) 1,180,435
Income Statement
Revenue n/a Gross Profit n/a Operating Income 10.46M Net Income -79.28M EBITDA 10.46M EBIT -81.42M Earnings Per Share (EPS) -1.23
Full Income Statement Balance Sheet The company has 61.58M in cash and 2.38M in
debt, giving a net cash position of 59.2M.
Cash & Cash Equivalents 61.58M Total Debt 2.38M Net Cash 59.2M Retained Earnings -231.72M Total Assets 341.1M Working Capital 212.93M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -18.29M
and capital expenditures -54.41M, giving a free cash flow of -72.71M.
Operating Cash Flow -18.29M Capital Expenditures -54.41M Free Cash Flow -72.71M FCF Per Share -1.13
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields CATX does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for CATX is $12,
which is 222.6% higher than the current price. The consensus rating is "Buy".
Price Target $12 Price Target Difference 222.6% Analyst Consensus Buy Analyst Count 10
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jun 17, 2024. It was a
backward
split with a ratio of 1:10.
Last Split Date Jun 17, 2024 Split Type backward Split Ratio 1:10
Scores Altman Z-Score 2.2 Piotroski F-Score 3
